Study of ropeginterferon alfa-2b for polycythemia vera
Treatments studied
Part of Blood & lymphatic clinical trials.
This study looks at real-world data from people with polycythemia vera who have taken ropeginterferon alfa-2b (BESREMI). It aims to understand how well the treatment works and how it affects patients in everyday medical practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with polycythemia vera.
- You have taken at least one dose of ropeginterferon alfa-2b (brand name BESREMI).
- Your medical records are complete and available for review.
- You are being treated at one of the participating study centers.
- You have agreed to take part in the study by signing a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a drug called ropeginterferon alfa-2b works for people with polycythemia vera. It aims to understand the drug's effects and safety when used as a first or later treatment option.
This study is testing a medicine called ropeginterferon alfa-2b for people with polycythemia vera (a blood condition) who do not have a swollen spleen that causes symptoms. It looks at how well the medicine works and how it affects your daily life through simple questionnaires.
This trial tests an experimental pill called bomedemstat for people with polycythemia vera who have not responded well to or could not tolerate hydroxyurea. It aims to see if the drug can help control red blood cell counts with fewer side effects.
This trial tests a combination of two medications, ropeginterferon alfa-2b and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough or has grown back while on ruxolitinib. The goal is to see if adding the newer drug can improve outcomes.
This trial tests a medicine called peginterferon for people with two blood disorders: essential thrombocythemia (too many platelets) and polycythemia vera (too many red blood cells). The goal is to see if peginterferon can help control these conditions and is safe.
This Phase 2 trial studies ropeginterferon alfa-2b (a type of interferon medicine) in adults with early, lower-risk myelofibrosis. The goal is to see if it can control the disease better or improve outcomes with an acceptable safety profile.
Hear when a new Polycytemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.